



## Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting

November 2, 2020

**KOL Call with Principal Investigator Christopher D. Riemann, M.D., Scheduled for November 17, 2020 at 4:00 pm Eastern Time**

CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 2, 2020-- [Lineage Cell Therapeutics, Inc.](#) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, will be hosting a call to discuss updated interim results from the Phase 1/2a study of its lead product candidate, [OpRegen®](#), with one of the study's principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD). [Christopher D. Riemann](#), M.D., Vitreoretinal Surgeon and Fellowship Director, [Cincinnati Eye Institute](#) (CEI) and University of Cincinnati School of Medicine, will present updated interim results from the ongoing Phase 1/2a study of OpRegen at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020) during the Original Paper Session on November 15, 2020. Dr. Riemann will participate in a call to discuss the interim results on November 17, 2020 at 4:00 pm Eastern Time / 1:00 pm Pacific Time. Interested parties can register for the event on the [Solebury Trout Events Page](#) and access the live webcast discussion on the [Events and Presentations](#) section of Lineage's website.

"We are fortunate to have an esteemed surgical expert available to discuss our updated interim data from the ongoing clinical trial of OpRegen for the treatment of dry AMD," stated Brian Culley, CEO. "Dr. Riemann's first-hand experience not only with OpRegen RPE cells, but also with the Orbit SDS delivery device, make him an ideal person to review data emerging from the ongoing OpRegen clinical study, which we expect to complete enrollment before year-end."

**Therapeutic Area Expert:** [Christopher D. Riemann, M.D.](#), Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine.

In collaboration with the other Retinal Surgeons at CEI, Dr. Riemann is a principal investigator or co-investigator for many Phase two and Phase three FDA trials. He specializes in medical and surgical vitreoretinal diseases including diabetic retinopathy, macular degeneration, retinal detachment, retinopathy of prematurity, vascular diseases of the retina, uveitis, histoplasmosis, complications of anterior segment surgery, endoscopic posterior segment surgery, and ocular trauma. Dr. Riemann is a member of the American Society of Retina Specialists, American Academy of Ophthalmology, Ohio State Medical Association, Cincinnati Academy of Medicine, Cincinnati Ophthalmology Society, and the Association for Research in Vision and Ophthalmology. His original research in the fields of Ophthalmology, Cardiology, and Endocrinology has been published in international peer reviewed scientific journals and has been presented at national scientific meetings. He has several patents for innovative surgical technologies and enjoys sharing his passion for the blend of engineering and medicine.

### About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study will enroll patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort, which is currently enrolling, will include patients with vision as high as 20/64. Cohort 4 also includes patients treated with a new "thaw-and-inject" formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additionally, for the patients in Cohort 4 that receive subretinal delivery of OpRegen utilizing the Gyroscope Orbit Subretinal Delivery System (Gyroscope Orbit SDS), objectives will include the evaluation of the safety of delivery of OpRegen using the Gyroscope Orbit SDS.

Recently, Lineage [reported](#) the first known finding of retinal tissue regeneration in a patient receiving OpRegen for the treatment of atrophic dry AMD. This unprecedented finding supports the view that dry AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable in atrophic end-stage disease patients. These findings were initially observed by an independent external advisor using multiple imaging technologies and were subsequently confirmed by the reading center and additional experts in the field of retinal imaging. The Company also has [observed](#) evidence of benefit in other patients, including increases in Best Corrected Visual Acuity (BCVA), reduction in the growth of GA, and increases in reading speed.

OpRegen is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of Lineage Cell Therapeutics, Inc.

### About Dry AMD

Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of \$10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.

### About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this

platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen<sup>®</sup>, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit [www.lineagecell.com](http://www.lineagecell.com) or follow the Company on Twitter [@LineageCell](https://twitter.com/LineageCell).

#### **Forward-Looking Statements**

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the expected enrollment timeline for Lineage's OpRegen trial. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage's business and other risks in Lineage's filings with the Securities and Exchange Commission (the SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage's periodic reports with the SEC, including Lineage's Annual Report on Form 10-K filed with the SEC on March 12, 2020 and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201102005240/en/): <https://www.businesswire.com/news/home/20201102005240/en/>

#### **Lineage Cell Therapeutics, Inc. IR**

Ioana C. Hone  
([ir@lineagecell.com](mailto:ir@lineagecell.com))  
(442) 287-8963

#### **Solebury Trout IR**

Gitanjali Jain Ogawa  
([Gogawa@troutgroup.com](mailto:Gogawa@troutgroup.com))  
(646) 378-2949

#### **Russo Partners – Media Relations**

Nic Johnson or David Schull  
([Nic.johnson@russopartnersllc.com](mailto:Nic.johnson@russopartnersllc.com))  
([David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com))  
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.